Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

Alzheimer's and Dementia

Volumn 9, Issue 5 SUPPL., 2013, Pages

  Johnson, Keith A ^a   Sperling, Reisa A ^a   Gidicsin, Christopher M ^a   Carmasin, Jeremy S ^a   Maye, Jacqueline E ^a   Coleman, Ralph E ^b   Reiman, Eric M ^c   Sabbagh, Marwan N ^d   Sadowsky, Carl H ^e   Fleisher, Adam S ^c,f   Murali Doraiswamy, P ^b   Carpenter, Alan P ^g   Clark, Christopher M ^g   Joshi, Abhinay D ^g   Lu, Ming ^g   Grundman, Michel ^f,h   Mintun, Mark A ^g   Pontecorvo, Michel J ^g   Skovronsky, Daniel M ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g AVID RADIOPHARMACEUTICALS   (United States)

^h Global R and D Partners   (United States)

Author keywords

Alzheimer's disease; Amyloid; Amyvid; Florbetapir; Mesh; PET

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; FLORBETAPIR F 18; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; AMYLOID PROTEIN; ANILINE DERIVATIVE; APOLIPOPROTEIN E4; FLUORINE; STILBENE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CT SPECT SCANNER; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGING; CLINICAL TRIAL; GENETICS; MENTAL HEALTH; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; STILBENES;

EID: 84885597030     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.10.007     Document Type: Article

References (56)

1. H. Braak, and E. Braak Diagnostic criteria for neuropathologic assessment of Alzheimer's disease Neurobiol Aging 18 1997 S85 S88
2. B.T. Hyman The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies Neurobiol Aging 18 1997 S27 S32
3. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319
4. K.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, and P. Maruff Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 130 2007 2837 2844
5. D.M. Rentz, J.J. Locascio, J.A. Becker, E.K. Moran, E. Eng, and R.L. Buckner Cognition, reserve, and amyloid deposition in normal aging Ann Neurol 67 2010 353 364
6. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/β-amyloid ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349
7. B.J. Bacskai, M.P. Frosch, S.H. Freeman, S.B. Raymond, J.C. Augustinack, and K.A. Johnson Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report Arch Neurol 64 2007 431 434
8. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, and N.D. Tsopelas Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645
9. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
10. H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, and I. Savitcheva Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2006 2856 2866
11. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, and A. Wall PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 2008 1456 1465
12. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Någren Conversion of amyloid positive and negative MCI to AD over 3 years: a C-PIB PET study Neurology 73 2009 754 760
13. D.A. Wolk, J.C. Price, J.A. Saxton, B.E. Snitz, J.A. James, and O.L. Lopez Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 65 2009 557 568
14. H.J. Aizenstein, R.D. Nebes, J.A. Saxton, J.C. Price, C.A. Mathis, and N.D. Tsopelas Frequent amyloid deposition without significant cognitive impairment among the elderly Arch Neurol 65 2008 1509 1517
15. J.A. Becker, J. Hedden, J. Carmasin, J. Maye, D.M. Rentz, and D. Putcha Amyloid-β associated cortical thinning in clinically normal elderly Ann Neurol 69 2011 1032 1042
16. S.N. Gomperts, D.M. Rentz, E. Moran, J.A. Becker, J.J. Locascio, and W.E. Klunk Imaging amyloid deposition in Lewy body diseases Neurology 71 2008 903 910
17. R.A. Sperling, P.S. Laviolette, K. O'Keefe, J. O'Brien, D.M. Rentz, and M. Pihlajamaki Amyloid deposition is associated with impaired default network function in older persons without dementia Neuron 63 2009 178 188
18. G.S. Pearl Diagnosis of Alzheimer's disease in a community hospital-based brain bank program South Med J 90 1997 720 722
19. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
20. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
21. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
22. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
23. S.R. Choi, G. Golding, Z. Zhuang, W. Zhang, N. Lim, and F. Hefti Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain J Nucl Med 50 2009 1887 1894
24. D.F. Wong, P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, and H.T. Ravert In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18) J Nucl Med 51 2010 913 920
25. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun Use of florbetapir-PET for imaging β-amyloid pathology JAMA 305 2011 275 283
26. C.M. Clark, M.J. Pontecorvo, T.J. Beach, B.J. Bedell, R.E. Coleman, and P.M. Doraiswamy Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study Lancet Neurol 11 2012 669 678
27. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
28. M.F. Folstein, S.E. Folstein, and P.R. McHugh Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician J Psychiatry Res 12 1975 189 198
29. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, and M. Grundman An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 1997 S33 S39
30. W.G. Rosen, R.C. Mohs, and K.L. Davis A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364
31. J.C. Morris The Clinical Dementia Rating Scale (CDR): current version and scoring rules Neurology 43 1993 2412 2414
32. D. Wechsler Wechsler Memory Scale-Revised 1987 The Psychological Corporation San Antonio, TX
33. D. Wechsler Wechsler Adult Intelligence Scale-Revised 1981 The Psychological Corporation San Antonio, TX
34. J.C. Morris, A. Heyman, R.C. Mohs, J.P. Hughes, G. van Belle, and G. Fillenbaum The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part I. Clinical and neuropsychological assessment of Alzheimer's Disease Neurology 39 1989 1159 1165
35. A.D. Joshi, M.J. Pontecorvo, C.M. Clark, A.P. Carpenter, D.L. Jennings, and C.H. Sadowsky Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects J Nucl Med 53 2012 378 384
36. R.A. Sperling, K.A. Johnson, P.M. Doraiswamy, E.M. Reiman, A.S. Fleisher, and M.N. Sabbagh Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiol Aging 34 2013 822 831
37. M. Gearing, J.A. Schneider, G.W. Rebeck, B.T. Hyman, and S.S. Mirra Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates Neurology 45 1995 1985 1990
38. A. Lim, D. Tsuang, and W. Kukull Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series J Am Geriatr Soc 47 1999 564 569
39. D.A. Bennett, J.A. Schneider, J.L. Bienias, D.A. Evans, and R.S. Wilson Mild cognitive impairment is related to Alzheimer's disease pathology and cerebral infarctions Neurology 64 2005 834 841
40. C.M. Hulette, K.A. Welsh-Bohmer, M.G. Murray, A.M. Saunders, D.C. Mash, and L.M. McIntyre Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals J Neuropathol Exp Neurol 57 1998 1168 1174
41. D.S. Knopman, J.E. Parisi, A. Salviati, M. Floriach-Robert, B.F. Boeve, and R.J. Ivnik Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 62 2003 1087 1095
42. R.C. Petersen, J.E. Parisi, D.W. Dickson, K.A. Johnson, D.S. Knopman, and B.F. Boeve Neuropathologic features of amnestic mild cognitive impairment Arch Neurol 63 2006 665 672
43. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 1999 358 368
44. D.X. Rasmusson, J. Brandt, C. Steele, J.C. Hedreen, J.C. Troncoso, and M.F. Folstein Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology Alzheimer Dis Assoc Disord 10 1996 180 188
45. F.A. Schmitt, D.G. Davis, D.R. Wekstein, C.D. Smith, J.W. Ashford, and W.R. Markesbery "Preclinical" AD revisited: neuropathology of cognitively normal older adults Neurology 55 2000 370 376
46. H. Barthel, H.J. Gertz, S. Dresel, O. Peters, P. Bartenstein, and K. Buerger Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Lancet Neurol 10 2011 424 435
47. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
48. R. Vandenberghe, K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, and E. Triau 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 68 2010 319 329
49. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
50. N.J. Cairns, M.D. Ikonomovic, T. Benzinger, A.M. Fagan, A.R. Shah, and L.T. Reinwald Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch Neurol 66 2009 1557 1562
51. V. Leinonen, I. Alafuzoff, S. Aalto, T. Suotunen, S. Savolainen, and K. Någren Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B Arch Neurol 65 2008 1304 1309
52. R.F. Rosen, B.J. Ciliax, T.S. Wingo, M. Gearing, J. Dooyema, and J.J. Lah Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease Acta Neuropathol 119 2010 221 233
53. P.M. Doraiswamy, R.A. Sperling, and R.E. Coleman Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multi-center study Neurology 79 2012 1636 1644
54. A.S. Fleisher, K. Chen, X. Liu, N. Ayutyanont, A. Roontiva, and P. Thiyyagura Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 34 2013 1 12
55. C.R. Jack, V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
56. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci USA 106 2009 6820 6825